Abstract
Baseline CD4 cell counts and human immunodeficiency virus (HIV)-1 RNA levels have been shown to predict immunologic and virologic responses in HIV-infected patients receiving antiretroviral therapy. In our randomized, double-blind, comparative trial, 653 antiretroviral therapy-naive patients received lopinavir/ritonavir or nelfinavir, plus stavudine and lamivudine, for up to 96 weeks. The risk of loss of virologic response was significantly higher for nelfinavir-treated patients than for lopinavir/ritonavir-treated patients (Cox model hazard ratio, 2.2; 95% confidence interval, 1.7-3.0; P<.001). For nelfinavir-treated patients, but not for lopinavir/ritonavir-treated patients, higher baseline HIV-1 RNA levels and lower baseline CD4 cell counts were associated with a higher risk of loss of virologic response.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase III
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / pharmacology
-
Anti-HIV Agents / therapeutic use*
-
CD4 Lymphocyte Count
-
Double-Blind Method
-
Drug Resistance, Viral
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
HIV Infections / virology
-
HIV-1 / drug effects*
-
Humans
-
Lamivudine / therapeutic use
-
Lopinavir
-
Male
-
Nelfinavir / pharmacology
-
Nelfinavir / therapeutic use*
-
Predictive Value of Tests
-
Pyrimidinones / pharmacology
-
Pyrimidinones / therapeutic use*
-
RNA, Viral / blood
-
Risk Factors
-
Ritonavir / pharmacology
-
Ritonavir / therapeutic use*
-
Sex Characteristics
-
Stavudine / therapeutic use
-
Viral Load
Substances
-
Anti-HIV Agents
-
Pyrimidinones
-
RNA, Viral
-
Lopinavir
-
Lamivudine
-
Stavudine
-
Nelfinavir
-
Ritonavir